BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18504250)

  • 1. Does oxaliplatin and paclitaxel combination show an activity of some extent in pretreated patients with germ-cell tumors?: Reply to the article "A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors" by C. Theodore et al. (Ann Oncol 2008; doi: 10.1093/annonc/mdn122).
    Necchi A; Nicolai N; Salvioni R
    Ann Oncol; 2008 Aug; 19(8):1509. PubMed ID: 18504250
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
    Theodore C; Chevreau C; Yataqhene Y; Fizazi K; Delord JP; Lotz JP; Geoffrois L; Kerbrat P; Bui V; Flechon A
    Ann Oncol; 2008 Aug; 19(8):1465-1469. PubMed ID: 18385203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
    Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
    Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
    De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
    Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    Farmakis D; Pectasides M; Pectasides D
    Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
    Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
    Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
    Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
    Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
    Kollmannsberger C; Nichols C; Bokemeyer C
    Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin in non-seminomatous germ-cell tumors.
    Fizazi K; Culine S; Chen I
    Ann Oncol; 2004 Aug; 15(8):1295. PubMed ID: 15277272
    [No Abstract]   [Full Text] [Related]  

  • 11. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
    Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
    World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
    Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors.
    Jain A; Brames MJ; Vaughn DJ; Einhorn LH
    Am J Clin Oncol; 2014 Oct; 37(5):450-3. PubMed ID: 23388561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
    Perez-Somarriba M; Moreno-Tejero ML; Rozas MI; Pelaez I; Madero L; Lassaletta A
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28089. PubMed ID: 31724795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
    Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-cell tumors.
    Kondagunta V; Galsky MD; Sonpavde G
    N Engl J Med; 2007 Oct; 357(17):1773; author reply 1773-4. PubMed ID: 17969229
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
    Shamash J; Powles T; Mutsvangwa K; Wilson P; Ansell W; Walsh E; Berney D; Stebbing J; Oliver T
    Ann Oncol; 2007 May; 18(5):925-30. PubMed ID: 17355956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.